|
1
|
Perren A, Couvelard A, Scoazec JY, Costa
F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense
RT, et al: ENETS consensus guidelines for the standards of care in
neuroendocrine tumors: Pathology: Diagnosis and prognostic
stratification. Neuroendocrinology. 105:196–200. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rickman DS, Beltran H, Demichelis F and
Rubin MA: Biology and evolution of poorly differentiated
neuroendocrine tumors. Nat Med. 23:1–10. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Cives M and Strosberg JR:
Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin.
68:471–487. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Soczomski P, Jurecka-Lubieniecka B,
Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska
M, Pawlaczek A, Bednarczuk T and Jarzab B: A direct comparison of
patients with hereditary and sporadic pancreatic neuroendocrine
tumors: Evaluation of clinical course, prognostic factors and
genotype-phenotype correlations. Front Endocrinol (Lausanne).
12(681013)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Guilmette JM and Nosé V: Neoplasms of the
neuroendocrine pancreas: An update in the classification,
definition, and molecular genetic advances. Adv Anat Pathol.
26:13–30. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Krug S, Schrader J and Rinke A: Updates on
Diagnostic and therapeutic management of gastrointestinal and
pancreatic NET. Cancers (Basel). 14(2628)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kurita Y, Kobayashi N, Hara K, Mizuno N,
Kuwahara T, Okuno N, Haba S, Tokuhisa M, Hasegawa S, Kubota K, et
al: Clinical outcomes of everolimus rechallenge in patients with
pancreatic neuroendocrine neoplasms with no other treatment
options. Cancers (Basel). 14(5669)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Camus B, Cottereau AS, Palmieri LJ,
Dermine S, Tenenbaum F, Brezault C and Coriat R: Indications of
peptide receptor radionuclide therapy (PRRT) in
gastroenteropancreatic and pulmonary neuroendocrine tumors: An
updated review. J Clin Med. 10(1267)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yu F, Fu J, Zhang C, Wu W, Ai S, Yao X,
Meng Q, Huang Y, Lu G, Wang F and Qu W: Use of chromogranin a for
monitoring patients with pancreatic neuroendocrine neoplasms.
Pancreas. 50:882–889. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fuksiewicz M, Kowalska M,
Kolasinska-Cwikla A and Kotowicz B: Serum levels of neuron-specific
enolase as a prognostic factor for disease progression in patients
with GET/NEN in the pancreas and the small intestine. Endocr
Connect. 11(e210647)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Koneczny I and Herbst R: Myasthenia
gravis: Pathogenic effects of autoantibodies on neuromuscular
architecture. Cells. 8(671)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lazaridis K and Tzartos SJ: Myasthenia
gravis: Autoantibody specificities and their role in MG management.
Front Neurol. 11(596981)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lazaridis K and Tzartos SJ: Autoantibody
specificities in myasthenia gravis; Implications for improved
diagnostics and therapeutics. Front Immunol. 11(212)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yi JS, Guptill JT, Stathopoulos P, Nowak
RJ and O'Connor KC: B cells in the pathophysiology of myasthenia
gravis. Muscle Nerve. 57:172–184. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shelly S, Agmon-Levin N, Altman A and
Shoenfeld Y: Thymoma and autoimmunity. Cell Mol Immunol. 8:199–202.
2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ali M, Riad M, Adhikari P, Bhattarai S,
Gupta A, Ali E and Mostafa JA: Association between myasthenia
gravis and systemic lupus erythematosus as a comorbid state.
Cureus. 13(e14719)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tanovska N, Novotni G, Sazdova-Burneska S,
Kuzmanovski I, Boshkovski B, Kondov G, Jovanovski-Srceva M,
Kokareva A and Isjanovska R: Myasthenia gravis and associated
diseases. Open Access Maced J Med Sci. 6:472–478. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Verwijst J, Westerberg E and Punga AR:
Cancer in myasthenia gravis subtypes in relation to
immunosuppressive treatment and acetylcholine receptor antibodies:
A Swedish nationwide register study. Eur J Neurol. 28:1706–1715.
2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hermans MA, Stelten BM, Haak HR, de Herder
WW and Dercksen MW: Two patients with a neuroendocrine tumour of
the small intestine and paraneoplastic myasthenia gravis.
Endocrinol Diabetes Metab Case Rep. 2014(140013)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gay SA and Nawras SA: Myasthenia gravis
with coexisting primary pancreatic neuroendocrine tumor in a young
female patient. Am J Gastroenterol. 106(S235)2011.
|
|
21
|
Wong SH, Huda S, Vincent A and Plant GT:
Ocular myasthenia gravis: Controversies and updates. Curr Neurol
Neurosci Rep. 14(421)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Alhaidar MK, Abumurad S, Soliven B and
Rezania K: Current treatment of myasthenia gravis. J Clin Med.
11(1597)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Farrugia ME and Goodfellow JA: A practical
approach to managing patients with myasthenia gravis-opinions and a
review of the literature. Front Neurol. 11(604)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim JA, Lim YM, Jang EH and Kim KK: A
patient with coexisting myasthenia gravis and lambert-eaton
myasthenic syndrome. J Clin Neurol. 8:235–237. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Oh SJ: Myasthenia gravis Lambert-Eaton
overlap syndrome. Muscle Nerve. 53:20–26. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Falconi M, Eriksson B, Kaltsas G, Bartsch
DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G,
Klöppel G, et al: ENETS consensus guidelines update for the
management of patients with functional pancreatic neuroendocrine
tumors and non-functional pancreatic neuroendocrine tumors.
Neuroendocrinology. 103:153–171. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Skeie GO and Romi F: Paraneoplastic
myasthenia gravis: Immunological and clinical aspects. Eur J
Neurol. 15:1029–1033. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Graus F, Delattre JY, Antoine JC, Dalmau
J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch,
Verschuuren JJ, et al: Recommended diagnostic criteria for
paraneoplastic neurological syndromes. J Neurol Neurosurg
Psychiatry. 75:1135–1140. 2004.PubMed/NCBI View Article : Google Scholar
|
